As you surely know, Seemingly, NP did apply for Br

As you surely know, Seemingly, NP did apply for Breakthrough Designation based on this trial. It did have slightly better results that Trodelvy and as I recall a better safety profile, but the FDA turned us down. Ohm was of the opinion that we should have gotten that designation, which means we should have gotten that designation. Perhaps it was too small a trial, or NP's confusing PR (where he described the improvement of the subset, rather than the results of the whole) was not to the FDA's taste, or perhaps our friend Gilead had some influence on the call. It still rankles.